Stocktoria
Cocrystal Pharma, Inc. COCP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-03-12
Cocrystal Pharma, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $5.1M | $12.5M | $15.2M | $12.4M | $8.8M |
| Operating income | -$9.0M | -$17.9M | -$18.6M | -$38.8M | -$14.2M |
| Interest expense | — | — | -$640,000 | $2,000 | $4,000 |
| Net income | -$8.8M | -$17.5M | -$18.0M | -$38.8M | -$14.2M |
| EPS (diluted) | $-0.78 | $-1.72 | $-1.87 | $-4.77 | — |
| Operating cash flow | -$8.2M | -$16.5M | -$14.7M | -$21.4M | -$12.7M |
| Free cash flow | -$8.2M | -$16.5M | -$14.8M | -$21.5M | -$12.8M |
| Cash & equivalents | $7.0M | $9.9M | $26.4M | $37.1M | $58.7M |
| Total assets | $9.7M | $13.5M | $31.3M | $40.8M | $79.4M |
| Total liabilities | $3.4M | $3.9M | $4.9M | $1.3M | $1.8M |
| Shareholders' equity | $6.3M | $9.5M | $26.4M | $39.6M | $77.5M |
Source: SEC EDGAR filings · CIK 0001412486 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.